Senseonics Holdings (NYSE: SENS) reported Q1 EPS of ($0.16), $0.04 worse than the analyst estimate of ($0.12).

“In the first quarter, we achieved a significant milestone with the successful FDA panel advisory meeting and have made meaningful progress with commercial readiness activities in the United States. We have been simultaneously deepening our presence in the countries where Eversense is currently available and enhancing our offering with the recent addition of the extended life Eversense XL,” said Tim Goodnow, President and Chief Executive Officer of Senseonics. “In the remaining time in 2018, we anticipate launching Eversense in the United States, introducing Eversense XL across the European marketplace and initiating a pivotal trial for labeling of up to 180 days of wear in the United States.”

For earnings history and earnings-related data on Senseonics Holdings (SENS) click here.